AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

INOVIQ LTD Capital/Financing Update 2019

Jun 25, 2019

65112_rns_2019-06-25_b7dde72e-c1e7-416c-b8f5-fd2eaeed19b8.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [155 x 46] intentionally omitted <==

NON-RENOUNCEABE ENTITLEMENT OFFER DESPATCH OF OFFER DOCUMENT

Perth, Australia, 26 June 2019: Australian medical technology company BARD1 Life Sciences Limited (ASX:BD1) ( BARD1 or the Company ), is pleased to advise that the Offer Document and Entitlement and Acceptance Form in connection with its non-renounceable Entitlement Issue was despatched to Eligible Shareholders today.

Any enquiries regarding the Entitlement Offer should be directed to the Company Secretary on +618 93819550.

P Collinson

Company Secretary

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1’s vision is to detect cancer early and save lives. For more information on BARD1, see www.bard1.com.

BARD1 Life Sciences Limited (ABN 58 009 070 384) Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E [email protected] | W www.bard1.com